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Abstract Background Type 2 diabetes is a common diag-
nosis in care home residents that is associatedwith potentially
inappropriate prescribing and thus risk of additional suffering.
Previous studies found that diabetes medicines can be safely
withdrawn in care home residents, encouraging further
investigation of the potential for deprescribing amongst these
patients.ObjectivesDescribe comorbidities and medicine use
in care home residents with Type 2 diabetes; identify number
of potentially inappropriate medicines prescribed for these
residents using a medicines optimisation tool; assess clinical
applicability of the tool. Setting Thirty care homes for older
people, East Anglia, UK. Method Data on diagnoses and
medicines were extracted from medical records of 826 resi-
dents. Potentially inappropriate medicines were identified
using the tool ‘Optimising Safe and Appropriate Medicines
Use’. Twenty percent of results were validated by a care home
physician. Main outcome measure Number of potentially
inappropriate medicines.ResultsThe 106 residents with Type
2 diabetes had more comorbidities and prescriptions than
those without. Over 90 % of residents with Type 2 diabetes
had at least one potentially inappropriate medication. The
most commonwas absence of valid indication. The physician
unreservedly endorsed 39 % of the suggested deprescribing,
and would consider discontinuing all but one of the remaining
medicines following access to additional information. Con-
clusion UK care home residents with Type 2 diabetes had an
increased burden of comorbidities and prescriptions. The
majority of these patients were prescribed potentially inap-
propriate medicines. Validation by a care home physician
supported the clinical applicability of the medicines optimi-
sation tool.
Keywords Care homes  Deprescribing  Medicines
optimisation tool  Pharmacists  Potentially inappropriate
medicines  Type 2 diabetes mellitus
Impacts of practice
• The results from this study suggest that care home
residents with Type 2 diabetes have a higher burden of
comorbidities and polypharmacy than residents without
diabetes, thereby having increased risk for potentially
inappropriate prescribing.
• The evidence-based, pragmatic medicines optimisation
tool used in this study allows pharmacists to identify
medicines eligible for deprescribing for care home
residents with Type 2 diabetes, thus reducing polyphar-
macy and potentially adverse events following from it.
Introduction
In the UK, care homes for older people provide accom-
modation and nursing or personal care to those who need it.
These institutions are staffed 24 h a day, with or without
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qualified nursing staff, and are referred to as nursing homes
and residential homes respectively. Care home residents
generally have a limited life expectancy [1] and experience
high levels of disability, comorbidity and polypharmacy
[2]. Non-insulin-dependent diabetes, also known as Type 2
diabetes mellitus (T2DM), is reported to be among the ten
most common diagnoses, affecting 15 % of the care home
population [2].
T2DM is associated with a range of comorbidities and
complications [3, 4], deteriorating health and reducing
quality of life. In the general older population, diabetes has
been identified as a predictor of multiple medicine use [5]
and an independent risk factor for being prescribed
potentially inappropriate medicines or combinations of
these [6, 7]. Unnecessary or inappropriate medicines can
cause adverse events and additional suffering in this
already vulnerable group of patients. It is argued that
people with diabetes who suffer from multiple comor-
bidities, cognitive impairment or reside in a long-term
nursing facility may experience limited or uncertain benefit
from diabetes treatment [8, 9]. Concerns about overtreat-
ment with blood glucose lowering medicines have been
reported [10, 11] and a Swedish study suggests that dia-
betes medicines can be safely reduced or withdrawn in the
majority of these residents [11]. These findings indicate
that the potential for deprescribing should be investigated
to a greater extent in this population.
Deprescribing is defined by Reeve et al. [12] as «the
process of withdrawal of an inappropriate medication,
supervised by a health care professional with the goal of
managing polypharmacy and improving outcomes».
Deprescribing is increasingly acknowledged as an impor-
tant part of prescribing when managing patients with
multiple conditions and limited life expectancy [13–15].
Several tools exist to help determine medication appro-
priateness in older persons, the STOPP/START criteria
[16] perhaps being the most commonly used in UK set-
tings. However, it has been argued that whilst these criteria
are useful in aiding prescribing for healthier older persons,
they may be less suitable for use in settings where the
patients are frail, late in life, and suffer from multiple ill-
nesses [13]. Hence, there is a requirement for clearer
practical guidance that directly addresses appropriate
removal of medicines in these patients [13], that should be
founded on questions about whether the medicine is cur-
rently indicated, safe and beneficial considering comor-
bidities [17, 18]. The NHS PrescQIPP document
‘Optimising Safe and Appropriate Medicine Use’
(OSAMU), a pragmatic, evidence-based tool, developed to
allow for appropriately stopping or continuing medicines in
end of life, uses such an approach [19]. When used as a
resource in a care home setting, it has been shown to safely
contribute to a reduction in polypharmacy, inappropriate
medicines and potential adverse effects [20, 21]. In addi-
tion it contributed to a reduction in administration time,
waste and costs of medicines.
Aim of the study
This study aimed to investigate the potential for depre-
scribing in UK care home residents with T2DM. The
objectives set were (1) to describe the comorbidities and
medicine use in the residents with T2DM; (2) to describe
the number of potentially inappropriate medicines in these
residents using an evidence-based, pragmatic medicines
optimisation tool; and (3) to describe the clinical applica-
bility of the medicines optimisation tool used.
This study is a retrospective sub-analysis of data from
the CAREMED study, a cluster randomised controlled trial
investigating the impact of a multi-professional medication
review service (MMRS) within 30 care homes for older
people across East Anglia, UK between March 2011 and
March 2013 [22].
Details of inclusion and exclusion criteria, outcome
measures, data collection and ethical approval have been
described in a previous publication. Findings from the main
study have yet to be published.
Ethics approval
The CAREMED study was approved by the National
Health Service (NHS) Norfolk Research Ethics Committee
(REC reference 09/H0310/96).
Methods
Data extraction and analysis
CAREMED baseline data was extracted for all 826 resi-
dents living in the 30 care homes. Data included infor-
mation about the residents’ current medicines and active
medical problems, derived from their medical records at
the general practitioner’s (GP’s) surgery.
Demographics
Diabetes prevalence was determined by evidence of T2DM
documented as an active medical problem. Residents with
other types of diabetes were excluded from the study
population and further analysis. Comorbidity burden was
determined from the resident’s number of active medical
problems. All active medical problems in the dataset were
classified according to the 22 chapters of the International
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Statistical Classification of Diseases and Related Health
Problems 10th Revision (ICD-10) Version: 2010 [23].
Number of prescriptions was determined from the number
of unique medicines prescribed. Polypharmacy was defined
as prescription of C5 unique medicines. All medicines
were coded according to the Anatomical Therapeutic
Chemical (ATC) classification system [24].
Potential for deprescribing
The NHS PrescQIPP document OSAMU consists of 46
areas for medicine optimisation based on the drug classes
in the British National Formulary (BNF) chapters [19].
Based on the available CAREMED data, we identified that
35 of these areas were applicable to our population. For
counting purposes, one or several explicit criteria were
identified for each area by LMA in agreement with RLSK
(Online Resource 1). LMA and RLSK are pharmacists with
experience of clinical work and research in both commu-
nity pharmacies and care homes, with particular focus on
diabetes. Potentially inappropriate medicines (PIMs) were
identified by LMA based on the criteria derived from the
recommendations given in the OSAMU document (Online
Resource 2).
As a further validation of clinical applicability of the
OSAMU document a physician (CG) with clinical back-
ground from care homes, currently in involved in a large
multicentre-study on medicines optimisation in care homes
[25], assessed the identified PIMs for discontinuation for a
random sample of 20 % of the residents. Based on the
information available, the physician evaluated whether (1)
the medicine could be discontinued without further
question; (2) the medicine should potentially be discon-
tinued, but not before checking other parameters of
importance, e.g. laboratory values; (3) the medicine should
be changed to a more appropriate choice; or (4) the med-
icine should be continued.
Statistical analysis
Descriptive statistics were applied. Continuous variables
are presented as medians with range and/or 95 % confi-
dence intervals (CI), and categorical variables are pre-
sented as frequencies with percentages and/or 95 % CI.
The 95 % CI for the medians and percentages were esti-
mated by the 2.5 and 97.5 percentiles from a simple
bootstrap (10.000 datasets were randomly generated for
each CI). Non-overlapping CI was interpreted as significant
effects. The RAND function in Microsoft Excel 2010
(Microsoft, Redmond, WA, USA) was used to create the
random 20 % sample for validation. IBM SPSS Statistics
22.0 (IBM, Armonk, NY, USA) was used for all statistical
analysis, apart from bootstrapping, which was performed
using Python 2.7.
Results
Demographics, therapy and comorbidity burden
Of 826 residents, 109 had a registered diagnosis of DM.
Two residents with Type 1 DM and one resident with
steroid-induced diabetes were excluded, resulting in a total
study population of 823 residents, where 106 residents had
Table 1 Demographics, burden
of comorbidities and
prescriptions in care home
residents with and without
diabetes mellitus
Type 2 DM No DM
n = 106 n = 717
Median Range [95 % CI]a Median Range [95 % CI]a
Age, years 86 56–98 [84.5, 87.5] 88 39–104 [88.0, 89.0]
Age at admission, years 84 54–98 [81.0, 85.0] 86 36–103 [85.0, 86.0]
Number of active medical problems 6.5 2–16 [6.0, 7.0] 5 1–14 [4.0, 5.0]
Number of prescriptions 9 1–20 [8.5, 10.0] 7 0–27 [7.0, 7.0]
n % [95 % CI]b n % [95 % CI]b
Polypharmacyc 98 92.5 [86.7, 96.9] 534 74.5 [70.7, 78.1]
Nursing home residents 24 22.6 [8.3, 41.7] 170 23.7 [17.6, 30.0]
Women 70 66.0 [54.3, 77.1] 555 77.4 [73.9, 80.9]
DM diabetes mellitus
a Confidence intervals for median values. Non-overlapping confidence intervals are interpreted as statis-
tically significant differences
b Confidence intervals for percentages. Non-overlapping confidence intervals are interpreted as statistically
significant differences
c Polypharmacy is defined as prescription of C5 unique drug substances
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diagnosed T2DM (13 %). Table 1 compares residents with
T2DM to residents without DM. Residents with T2DM
were significantly younger and had a higher burden of both
comorbidities and prescriptions than residents without DM.
The top five ICD-10 classifications for residents with
T2DM, excluding diabetes, were I00-I99: circulatory dis-
eases (n = 82, 77.4 %), F00-F99: mental and behavioural
disorders (n = 52, 49.1 %), M00-M99: musculoskeletal
and connective tissue diseases (n = 43, 40.6 %), H00-H59:
eye diseases (n = 40, 37.7 %), and N00-N99: genitouri-
nary diseases (n = 37, 34.9 %). They were treated with the
following blood glucose lowering therapy: insulin only
(n = 10), insulin and oral antidiabetic drugs (OADs)
(n = 4), OADs only (n = 56), and no blood glucose low-
ering drugs (n = 36). The other most commonly prescribed
groups of medicines among these residents are listed in
Table 2.
Potential for deprescribing
Among the residents with T2DM, a total of 346 PIMs were
identified. The residents had from none to nine PIMs
(Table 3), with a median number of three PIMs. In total, 96
residents (90.6 %) were prescribed at least one PIM. Fre-
quency of PIMs by BNF classification is presented in
Table 4. The most frequent PIMs were (1) statins pre-
scribed without a valid indication (n = 50, 47.2 %); (2)
more than one antihypertensive prescribed (n = 43,
40.6 %); (3) laxatives prescribed without a valid indication
(n = 32, 30.2 %); (4) antidepressant prescribed without a
valid indication (n = 32, 30.2 %); and (5) H2 blockers/
proton pump inhibitors (PPI) prescribed without a valid
indication (n = 27, 26.5 %).
Within the 20 % random sample chosen for validation
by physician CG, a total of 67 PIMs were identified and 35
of these belonged to the top five frequent PIMs (Table 5).
Table 2 The most frequently
prescribed drug groups in care
home residents with Type 2
diabetes mellitus (n = 106)
ATC code Therapeutic group/substance Residents receiving therapy
N %
A10 Drugs used in diabetes 70 66.0
A10A Insulins and analogues 14 13.2
A10B Blood glucose lowering drugs, excl. insulins 60 56.6
A10BA02 Metformin 45 42.5
A10BB09 Gliclazide 26 24.5
N02 Analgesics 65 61.3
C10 Lipid modifying agents 61 57.5
B01 Antithrombotic agents 60 56.6
A06 Drugs for constipation 48 45.3
C03 Diuretics 46 43.4
D02 Emollients and protectives 45 42.5
N06 Psychoanaleptics 43 40.6
A02 Drugs for acid related disorders 41 38.7
C09 Agents acting on the renin-angiotensin system 38 35.8
B03 Antianaemic preparations 29 27.4
C01 Cardiac therapy 26 24.5
N05 Psycholeptics 26 24.5
C07 Beta blocking agents 25 23.6
A12 Mineral supplements 24 22.6
H03 Thyroid therapy 24 22.6
Table 3 Total frequency of
potentially inappropriate
medicines in care home resi-
dents with Type 2 diabetes
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Out of the total of 67 PIMs the physician agreed that 26 of
these could be discontinued without further question
(38.8 %). A common example of this was statins without a
valid indication. In the case of a further 40 PIMs (59.7 %)
the physician indicated that medicine discontinuation
should be considered, following access to other clinical
data. An example here was to check blood pressure before
deciding whether or not to discontinue excess antihyper-
tensives. The physician recommended that one PIM
(1.5 %) be changed to a different medicine. In this par-
ticular case, the combination of an SSRI with low-dose
aspirin gave the resident an increased risk of gastroin-
testinal bleeding and hence the physician recommended
keeping the ulcer prophylaxis, but replacing the H2 blocker
with a proton pump inhibitor. None of the PIMs were
considered for direct continuation.
Discussion
This study found that UK care home residents with T2DM
were younger and had a greater burden of active medical
problems, prescriptions and polypharmacy than residents
without diabetes. Using the NHS PrescQIPP document
OSAMU, PIMs were identified for nine out of ten residents
with T2DM, with the absence of a valid indication as the
most common reason. Based on the available data, a
physician with experience of care homes and medicines
Table 4 Frequency of potentially inappropriate medicines by classification of the British National Formulary, in residents with Type 2 diabetes
mellitus (n = 106)




Chapter 1—gastrointestinal system 4 70 20.2
Chapter 2—cardiovascular system 10 111 32.1
Chapter 3—respiratory system 3 1 0.3
Chapter 4—central nervous system 15 89 25.7
Chapter 5—infections 3 10 2.9
Chapter 6—bisphosphonates 1 9 2.6
Chapter 7—obstetrics, gynaecology and urinary
tract disorders
5 7 2.0
Chapter 9—nutrition and blood 2 24 6.9
Chapter 10—musculoskeletal and joint diseases 4 13 3.8
Chapter 11—eye 1 0 0.0
Chapter 12—ear, nose and oropharynx 1 1 0.3
Chapter 13—skin 1 11 3.2
Total 50 346 100.0
BNF British National Formulary
a Chapters omitted indicated that these were not applicable to our population
Table 5 Validation of deprescribing potential for the top five frequently prescribed potentially inappropriate medicines









Statin, no valid indication (107)a 50 12 12 0 0 0
Antihypertensive, more than one (105)a 43 7 0 7 0 0
Laxative, no valid indication (103b)a 32 7 0 7 0 0
Antidepressant, no valid indication (120a)a 32 4 0 4 0 0
H2 blocker/PPI, no valid indication (102)a 27 5 4 0 1 0
Total 184 35 16 18 1 0
PIM potentially inappropriate medicine, PPI proton pump inhibitor
a Numbers in parentheses indicate the assigned criteria number (Online resource 1)
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optimisation confirmed that 39 % of the PIMs could be
directly discontinued, and acknowledged a potential for
deprescribing in all but one of the remaining cases.
Our findings concur with previous studies showing that
older persons with diabetes have higher rates of comor-
bidities [26] and prescriptions [5, 27, 28] compared to the
general older population, thereby having increased risk for
potentially inappropriate prescribing. The proportion of
residents with at least one PIM is similar to that found for
the general UK care home population when using a similar
pragmatic approach for medicines review. The Northum-
bria Shine 2012 project, a prospective medicines optimi-
sation study involving both clinicians and residents, used
OSAMU as a resource in the shared decision making
process [21]. When performing an extensive medicine
review for 422 residents in 20 care homes in North
Tyneside, UK, they found that 90.5 % of the residents
required an intervention to their medicines [17, 21]. Stop-
ping medicines was the most common intervention,
required for seven out of ten residents [17, 21].
Failure to integrate comorbidities into clinical practice
guidelines, and limited guidance on treatment for frail
older patients are presented as leading reasons for the
prescribing cascade so often seen in this population
[29, 30]. Furthermore, frail elderly are normally excluded
from randomised controlled trials and other robust studies
that guidelines are built upon. Consequently, practitioners
have little or no evidence-based guidance for how to pre-
scribe for this vulnerable group of patients, and sometimes
feel pressured to follow guidelines not developed based on
the needs of these patients [30, 31].
It has been demonstrated that many medicines can be
safely discontinued in older patients without causing
adverse effects [11, 14, 17]. Still, concerns about with-
drawal effects and lack of guidance on how and when to
discontinue a medication discourage clinicians from
attempting to do so [31, 32]. Several healthcare practi-
tioners have expressed a need for deprescribing guidelines,
especially for prevention-oriented medicines, as they may
be less appropriate in the care home population [32]. In
particular, statins have even been considered harmful in
older patients, as low total cholesterol (\5.5 mmol/l) is
associated with increased total mortality in those aged
C80 years [18]. GPs sometimes choose not to follow rec-
ommended guidelines and refrain from prescribing statins
in patients with T2DM. Questions about whether statins
lead to improved quality of life, and concerns regarding
frailty, multimorbidity and short life expectancy, are listed
as the main reasons for this [33]. In our study, the physician
who evaluated the PIMs agreed to stop all statins in the
sample cases examined, for the same reasons.
In addition to evaluation of risk versus benefit of con-
tinued use of a medicine, the existence of a current
indication is of particular concern for healthcare practi-
tioners when considering deprescribing [32]. Four out of
the five most common PIMs in our population involved
medicines not having a valid indication. Similarly, no
current indication was reported as the top reason for
stopping medicines in the Northumbria Shine 2012 project
[17], and according to Barber et al. [34] incomplete
information in medical records is the prescribing error most
frequently occurring in UK care homes. Many care homes
receive prescribing services from multiple GPs, making
clear and complete information crucial for adequate fol-
low-up of the residents. A lack of information on indication
may increase the potential for medication errors, and may
also hamper deprescribing, as it adds to the uncertainty of
whether the medicine is appropriate or not, especially if it
is prescribed by a GP different to the one reviewing it. GPs
often feel reluctant to change or stop medicines prescribed
by colleagues, and also report to lack knowledge of geri-
atric pharmacotherapy [31].
In general, a lack of communication and team work
between the GP practice, the pharmacy and the care home,
and hence no integrated system for medicines management,
is the reality for many UK care homes [34]. Appointing a
lead GP for each care home and involving a pharmacist
overseeing and regularly reviewing medicines use, are
recommended to improve this [34]. Pharmacist involve-
ment is valued by both GPs and care home staff [17] and
can contribute to increased knowledge and awareness
around medicines, as well as improve quality of medicine
use [35]. The Northumbria Shine 2012 project demon-
strated that a review process led by a prescribing phar-
macist, where interventions were made available in the
electronic medical notes for the GPs to challenge after-
wards, was a cost-efficient approach. However, they
debated that involving the GP during rather than after the
review may result in even more interventions and greater
savings [17]. This may be difficult to achieve at all care
homes, and several clinical studies have shown that the
GPs’ acceptance rate for medicine interventions suggested
by pharmacists is generally high [17, 36, 37]. Although our
approach was theoretical rather than clinical, the physician
who evaluated the PIMs fully agreed with the pharmacist’s
suggestions for deprescribing in 39 % of the cases, and
acknowledged a potential for deprescribing in all but one of
the remaining cases.
As this study was a cross-sectional and retrospective
review of a selection of resident data from an RCT dataset,
it has its limitations. For instance, we did not have infor-
mation about the sequence of prescribing, information
about duration of active medical problems, or previous
medical problems and prescriptions. Neither did we have
access to clinical data, such as blood pressure, lipids,
weight and fluid intake. These data could have shed light
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on the appropriateness of even more therapies than we
included as part of our analysis, and thus have facilitated a
consideration of optimisation of therapy, not just the
potential for deprescribing. We know from previous studies
that blood glucose lowering therapy is not always optimal
in the care home population [10, 11]. Additional clinical
data could also have provided a better foundation for
assessing the applicability of the criteria, and thus have
given room for involving a more extensive team of clini-
cians to validate them. With a limited set of medical
information, we identified 346 medicines as potentially
inappropriate, where in a random sample a large proportion
was directly endorsed for discontinuation by an experi-
enced care home physician. If applied by clinical phar-
macists or GPs with full access to all necessary medical
information, maybe an even greater number of PIMs could
have been identified and discontinued, and other therapies
could also have been considered for optimisation.
We used a relatively new tool for evaluating appropri-
ateness of medicines in the care home population. As such,
comparison with other studies using other tools should be
done with care. However, we have only compared our
results to studies using similar, pragmatic approaches. In
addition, more well-known tools, such as the STOPP/
START criteria, have been considered less suitable when
seeking to optimise drug therapy in the very frail old [13].
The tool used in this study is evidence-based, takes into
account the complexity of care home residents and has
proven to be efficient in this population [20]. Even though
the sample size is small and performed in a limited geo-
graphical area, the resident population is comparable to
that of other studies investigating different aspects of
health status of care home residents both with and without
DM in other parts of the UK [2, 38]. Hence, there is no
reason to believe that the residents in this study are sig-
nificantly different from the overall UK care home
population.
The results of this study indicate that there is an
unfulfilled potential for deprescribing in care home resi-
dents with T2DM. A more clinical approach with com-
plete access to all relevant information and involvement
of a team of clinicians, assessing relevant outcomes such
as impact on glycaemic control and quality of life, should
be the goal for future studies. It would be interesting to
see if such a study gives similar results to those reported
here. As a final note, when targeting care home medicines
management, involvement of the resident should also be
considered. Together with the best current research evi-
dence and clinical expertise, the patient’s values and
preferences make up the triad for evidence-based medi-
cine [39].
Conclusion
UK care home residents with T2DM have an increased
burden of comorbidities, prescriptions and polypharmacy.
Using an evidence-based, pragmatic medicines optimisa-
tion tool, we identified that the majority of these residents
were prescribed at least one PIM. Validation of the PIMs
by an experienced care home physician supports the clin-
ical applicability of the ‘Optimising Safe and Appropriate
Medicines Use’ document.
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